SCHEMBL30765804

SCHEMBL30765804

CCCCOC(=O)Cn1c(SC)ncc(N[C@H](C)c2ccc3c(c2)oc2ccccc23)c1=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.40
GAA P10253 1/20 0.40
KMT2A Q03164 4/20 0.38
MEN1 O00255 3/20 0.38
MAPT P10636 3/20 0.36
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
ACHE P22303 3/20 0.35
XDH P47989 1/20 0.34
ATM Q13315 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
LMNA P02545 1/20 0.34
POLB P06746 1/20 0.34
SIRT3 Q9NTG7 1/20 0.34
GABRP O00591 1/20 0.34
GABRD O14764 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30766030 0.95 L3MBTL1 (0.40) L3MBTL1GAAKMT2AMEN1MAPT
SCHEMBL30765675 0.95 L3MBTL1 (0.40) L3MBTL1GAAKMT2AMEN1MAPT
SCHEMBL30765944 0.87 ALDH1A1 (0.37) L3MBTL1GAAKMT2AMEN1MAPT
SCHEMBL30765879 0.85 GAA (0.41) L3MBTL1GAAKMT2AMEN1MAPT
SCHEMBL30765510 0.84 L3MBTL1 (0.41) L3MBTL1GAAKMT2AMEN1MAPT
SCHEMBL30765758 0.83 L3MBTL1 (0.40) L3MBTL1GAAKMT2AMEN1MAPT
SCHEMBL30765977 0.83 GAA (0.51) L3MBTL1GAAKMT2AMEN1MAPT
SCHEMBL30765767 0.83 GAA (0.40) L3MBTL1GAAKMT2AMEN1MAPT
SCHEMBL30765472 0.83 MEN1 (0.42) L3MBTL1GAAKMT2AMEN1LMNA
SCHEMBL30765941 0.82 ALDH1A1 (0.37) L3MBTL1GAAKMT2AMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed